US EditionSwedish TIRmed Pharma raises 4,3m€ against atopic dermatitis - European Biotechnology Magazine
Summary by European-biotechnology.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Swedish TIRmed Pharma raises 4,3m€ against atopic dermatitis - European Biotechnology Magazine
TIRmed Pharma secures 4,3m€ to advance immunomodulatory treatment options for atopic dermatitis into clinical development. Stockholm-based TIRmed Pharma has closed this funding round, led by Sciety and its investment network, Sciety Venture Partners. The capital shall support the company’s progress toward clinical development of its novel treatment for atopic dermatitis. The post Swedish TIRmed Pharma raises 4,3m€ against atopic dermatitis appea…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
